Scientists from the University of Oxford studied what happens in the brains of mice after abrupt withdrawal of the antidepressant paroxetine. It turned out that in two areas linked to anxiety - the dorsal raphe nucleus and the ventral hippocampus - neuron activity increases two days after treatment ends. It was at that moment that the animals became more anxious. The work was published in the journal Neuropharmacology.

Paroxetine belongs to the selective serotonin reuptake inhibitors (SSRIs) - a class of antidepressants that block the reuptake of serotonin, a neurotransmitter involved in mood regulation. As a result, serotonin levels in the brain rise. However, abrupt discontinuation of SSRIs can cause withdrawal symptoms: increased anxiety, sleep disturbances, unusual sensations. They usually appear in the first days after stopping the medication and can last for weeks.

The new study involved male mice aged seven weeks. They were randomly divided into three groups of 12 animals each. Two groups received injections of paroxetine (10 mg/kg) for 12 days, and one received saline. Then one of the groups receiving the drug continued treatment for another two or five days, while the third group (withdrawal) was switched to saline. Two days after withdrawal, mice in the withdrawal group showed increased anxiety in the elevated plus maze test - a standard way of assessing anxiety-like behavior in rodents. Then some of the animals were euthanized and their brains were examined for the c-Fos protein. This protein serves as a marker of recent neuron activity: its amount increases when nerve cells are excited.

It turned out that two days after paroxetine withdrawal, activity was increased in the dorsal raphe nucleus (the main source of serotonin for the forebrain) and the ventral hippocampus. In other anxiety-related areas, such as the prefrontal cortex or amygdala, no changes were found. In the dorsal raphe nucleus, serotonin neurons were activated, including a subgroup that produces both serotonin and glutamate. The authors suggest that during withdrawal, serotonin neurons may suddenly be released from the inhibition they experienced during treatment, leading to a surge in their activity.

Five days after withdrawal, the anxiety-like behavior in the mice disappeared, activity in the ventral hippocampus and serotonin-glutamate neurons returned to normal, but serotonin neurons in the dorsal raphe nucleus remained more active. This means that activation of serotonin neurons alone is probably insufficient to produce anxiety, whereas ventral hippocampus activity coincided in time with the anxiety-like behavior.

"Our results suggest that under these conditions, paroxetine withdrawal is associated with a transient activation of an anxiety-promoting circuit limited to serotonin neurons of the dorsal raphe nucleus and the hippocampus. This circuit may contribute to symptoms such as anxiety that are characteristic of SSRI withdrawal syndrome," the authors conclude.

The study was conducted in mice, so its results cannot be automatically transferred to humans. In addition, only males were studied, and brains were analyzed in six to seven animals from each group, which may have limited the detection of subtle changes in other areas. Finally, c-Fos reflects only recent neuron activity, and these data cannot establish that the brain changes caused the anxiety-like behavior. The correlation between brain activity and behavior is a statistical association that by itself does not prove causation.

Source: PsyPost